Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 8, 2001, Pages 3717-3723

  Toft Nielsen, Mai Britt ^a,b   Damholt, Mette B ^a   Madsbad, Sten ^a   Hilsted, Linda M ^a   Hughes, Thomas E ^c   Michelsen, Birgitte K ^d   Holst, Jens J ^b,e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Novartis Institute for Biochemical Research   (United States)

^d HAGEDORN RESEARCH INSTITUTE   (Denmark)

^e Biotechnology Center for Signal Peptide Research   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCOSE; INSULIN; PANCREAS POLYPEPTIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HORMONE RELEASE; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENCE;

EID: 0034880655     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.8.7750     Document Type: Article

References (53)

1. Truncated glucagon-like peptide-1, an insulin-releasing hormone from the distal gut
2. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
3. Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and stomach
4. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man
5. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans
6. Truncated GLP-1 (Proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
7. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
8. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
9. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
10. Exendin-4 stimulates β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats
11. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene
12. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinitropic action in glucagon-like peptide 1 receptor -/- mice
13. Glucagon-like peptide-1 has physiological role in the control of postprandial glucose in humans
14. Abscence of incretin effect in obese type II and diminished effect in lean type II and obese subjects
15. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
16. Immunoreactive gastric inhibitory polypeptide
17. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects
18. Preserved incretin effect of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabtes mellitus
19. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients
20. Attenuated GLP-1 secretion in obesity: Cause or consequence?
21. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy
22. Release of GLP-1 [7-36 amide] after oral glucose in relation to glucose tolerance and sex
23. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins
24. Proglucagon products in plasma from non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginine
25. Distal small bowel hormones: Correlation with fasting antroduodenal motility and gastric emptying
26. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 responses to oral glucose in postmenopausal women with impairs glucose tolerance
27. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects
28. Autonomic neuropathy. Its diagnosis and prognosis
29. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Summary and recommendations
30. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans
31. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics
32. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
33. Vagal, cholinergic regulation of pancreatic polypeptide secretion
34. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay
35. A microflourometric method for the determination of free fatty acids in plasma
36. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice
37. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop
38. Peptones stimulate both the secretion of the incretin hormone Glucagon-like peptide 1 and the transcription of the proglucagon gene
39. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion
40. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids
41. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy
42. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose)
43. Gastric emptying in diabetes mellitus: Relationship to blood-glucose control
44. Gastric and oesophageal emptying in obesity
45. Influence of gender and menopause on gastric emptying and motility
46. Gastrointestinal function in obesity: Motility, secretion and absorption following a liquid test meal
47. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
48. Dipeptidyl peptidase IV inhibitors: Mechanism of action involves 'rescue' of the biologically intact version of both incretin hormones in the conscious pig
49. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
50. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
51. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
52. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms